JP7857914B2 - Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物 - Google Patents
Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物Info
- Publication number
- JP7857914B2 JP7857914B2 JP2023507923A JP2023507923A JP7857914B2 JP 7857914 B2 JP7857914 B2 JP 7857914B2 JP 2023507923 A JP2023507923 A JP 2023507923A JP 2023507923 A JP2023507923 A JP 2023507923A JP 7857914 B2 JP7857914 B2 JP 7857914B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cancer
- halogen
- mmol
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026001041A JP2026082834A (ja) | 2020-08-04 | 2026-01-06 | Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202041033326 | 2020-08-04 | ||
| IN202041033326 | 2020-08-04 | ||
| PCT/IB2021/057089 WO2022029617A1 (en) | 2020-08-04 | 2021-08-03 | 6-substituted pyridazine compounds as smarca2 and/or smarca4 degraders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026001041A Division JP2026082834A (ja) | 2020-08-04 | 2026-01-06 | Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023536504A JP2023536504A (ja) | 2023-08-25 |
| JP2023536504A5 JP2023536504A5 (cg-RX-API-DMAC7.html) | 2024-08-09 |
| JP7857914B2 true JP7857914B2 (ja) | 2026-05-13 |
Family
ID=80117730
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507923A Active JP7857914B2 (ja) | 2020-08-04 | 2021-08-03 | Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物 |
| JP2026001041A Pending JP2026082834A (ja) | 2020-08-04 | 2026-01-06 | Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026001041A Pending JP2026082834A (ja) | 2020-08-04 | 2026-01-06 | Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12570650B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4192835A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7857914B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230061349A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116529250A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021320052A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023002089A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3188024A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300387A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023001445A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022029617A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US12624044B2 (en) | 2019-06-10 | 2026-05-12 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2021133917A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| US11679109B2 (en) | 2019-12-23 | 2023-06-20 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| US12606568B2 (en) | 2020-12-09 | 2026-04-21 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| AU2024348074A1 (en) | 2023-09-27 | 2026-04-30 | Haisco Pharmaceutical Group Co., Ltd. | Pyrazole carboxylic acid derivative and use thereof in medicine |
| WO2025196686A1 (en) * | 2024-03-20 | 2025-09-25 | Aurigene Oncology Limited | Fused bicyclic compounds as smarca2 and/or smarca4 degraders |
| CN119874808B (zh) * | 2025-01-02 | 2026-04-17 | 四川大学 | 一种靶向smarca蛋白降解的化合物及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195201A1 (en) | 2018-04-01 | 2019-10-10 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| WO2019207538A1 (en) | 2018-04-26 | 2019-10-31 | Aurigene Discovery Technologies Limited | Pyridazine derivatives as smarca2/4 degraders |
| JP2023510746A (ja) | 2020-01-10 | 2023-03-15 | アムジエン・インコーポレーテツド | Smarca2-vhl分解剤 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2952188A1 (en) * | 2014-06-20 | 2015-12-23 | Aurigene Discovery Technologies Limited | Substituted indazole compounds as irak4 inhibitors |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3319944A4 (en) * | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| KR20190140438A (ko) * | 2017-02-28 | 2019-12-19 | 에피자임, 인코포레이티드 | 암 치료를 위한 smarca2의 저해 |
-
2021
- 2021-08-03 MX MX2023001445A patent/MX2023001445A/es unknown
- 2021-08-03 WO PCT/IB2021/057089 patent/WO2022029617A1/en not_active Ceased
- 2021-08-03 JP JP2023507923A patent/JP7857914B2/ja active Active
- 2021-08-03 KR KR1020237005345A patent/KR20230061349A/ko active Pending
- 2021-08-03 US US18/019,721 patent/US12570650B2/en active Active
- 2021-08-03 AU AU2021320052A patent/AU2021320052A1/en active Pending
- 2021-08-03 IL IL300387A patent/IL300387A/en unknown
- 2021-08-03 BR BR112023002089A patent/BR112023002089A2/pt unknown
- 2021-08-03 EP EP21852975.8A patent/EP4192835A4/en active Pending
- 2021-08-03 CA CA3188024A patent/CA3188024A1/en active Pending
- 2021-08-03 CN CN202180068383.4A patent/CN116529250A/zh active Pending
-
2026
- 2026-01-06 JP JP2026001041A patent/JP2026082834A/ja active Pending
- 2026-02-22 US US19/546,365 patent/US20260184705A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195201A1 (en) | 2018-04-01 | 2019-10-10 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| WO2019207538A1 (en) | 2018-04-26 | 2019-10-31 | Aurigene Discovery Technologies Limited | Pyridazine derivatives as smarca2/4 degraders |
| JP2023510746A (ja) | 2020-01-10 | 2023-03-15 | アムジエン・インコーポレーテツド | Smarca2-vhl分解剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2026082834A (ja) | 2026-05-19 |
| WO2022029617A1 (en) | 2022-02-10 |
| MX2023001445A (es) | 2023-05-08 |
| EP4192835A1 (en) | 2023-06-14 |
| CA3188024A1 (en) | 2022-02-10 |
| IL300387A (en) | 2023-04-01 |
| BR112023002089A2 (pt) | 2023-02-28 |
| US20240018134A1 (en) | 2024-01-18 |
| AU2021320052A1 (en) | 2023-03-23 |
| US12570650B2 (en) | 2026-03-10 |
| CN116529250A (zh) | 2023-08-01 |
| EP4192835A4 (en) | 2024-08-21 |
| JP2023536504A (ja) | 2023-08-25 |
| US20260184705A1 (en) | 2026-07-02 |
| KR20230061349A (ko) | 2023-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026082834A (ja) | Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物 | |
| US12371426B2 (en) | Pyridazine derivatives as SMARCA2/4 degraders | |
| CN111285850B (zh) | 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用 | |
| EP2964223B1 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
| CN118005656A (zh) | Kras g12c突变蛋白嘧啶并噻喃二酮类抑制剂的制备及其应用 | |
| EP3686196B1 (en) | Polycyclic compound acting as ido inhibitor and/or ido-hdac dual inhibitor | |
| AU2024360867A1 (en) | Substituted tricyclic compounds as kras degraders | |
| EP4212522A1 (en) | Compounds for suppressing egfr mutant cancer and pharmaceutical use thereof | |
| CN112745298B (zh) | 多取代异吲哚啉类化合物、其制备方法、药物组合物及用途 | |
| AU2018269268B2 (en) | Crystal of benzofuran derivative free base and preparation method | |
| JP2024511342A (ja) | フラン縮合環置換グルタルイミド系化合物 | |
| WO2024078581A1 (en) | Selective bcl-xl protac compounds and uses thereof | |
| WO2021041970A1 (en) | Perk inhibiting imidazolopyrazine compounds | |
| EP3617204A1 (en) | Indoleamine 2,3-dioxygenase inhibitor and application | |
| EA052684B1 (ru) | 6-замещенные пиридазиновые соединения в качестве деструкторов smarca2 и/или smarca4 | |
| RU2845145C1 (ru) | Соединения для подавления рака с мутацией egfr и их фармацевтическое применение | |
| JP2025506452A (ja) | Smarca2及び/又はsmarca4分解剤としての3-置換ピリダジン化合物 | |
| KR20250170567A (ko) | 치환된 아세틸렌 화합물 유도체 및 이의 약제학적 용도 | |
| WO2026076223A1 (en) | Therapeutic compounds and methods of use thereof | |
| WO2025094065A1 (en) | Amino-substituted pyridazine compounds as smarca2 and/or smarca4 degraders | |
| EP4512807A1 (en) | Bicycloamine carboxamide derivative | |
| CN122059906A (zh) | 用于抑制ptpn蛋白的化合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230530 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240801 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240801 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250515 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250604 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250904 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251006 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260106 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260406 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260427 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7857914 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |